Follow us on  LinkedFit for Health LinkedIN

In the scope of PHC14: How detailed should be the submitted budget in such a case?

Question details: 
In the scope of PHC14: as the clinical development is depending on the data that will be obtained in preclinical studies, it will be difficult to have a precise budget to submit. How detailed should be the submitted budget in such a case? How detailed must be the study information that we will submit to H2020?
Answer: 

For PHC 14 (rare diseases) you are advised to contact EMA very early in the process. This is: before submitting stage 2 you MUST HAVE received orphan drug designation, so start contacting EMA today! http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/gen... http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/gen...